Suppr超能文献

氯喹和羟氯喹在治疗性使用或过量使用后的毒性。

Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.

机构信息

Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.

出版信息

Clin Toxicol (Phila). 2021 Jan;59(1):12-23. doi: 10.1080/15563650.2020.1817479. Epub 2020 Sep 22.

Abstract

INTRODUCTION

While chloroquine, a derivative of quinine, has been used as an antimalarial for 70 years, hydroxychloroquine is now used to treat conditions such as rheumatoid arthritis and systemic lupus erythematosus. In 2020, hydroxychloroquine (and to a lesser extent chloroquine) also received attention as a possible treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During investigation for treating coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, concerns for serious adverse events arose.

OBJECTIVE

We review the toxicity associated with hydroxychloroquine and chloroquine use both short-term and long-term and in overdose.

METHODS

Medline ( OVID) was searched from its inception through June 7 2020 using the following as either MeSH or keyword terms: ("Chloroquine/" or "Hydroxychloroquine/") AND ("Adverse Drug Event/" or "Toxicities, Drug/" or "Toxic.mp." or "Toxicity.mp." or "Overdose.mp."). We limited resultant articles to those published in English and reporting on Human subjects. This search yielded 330 articles, of which 57 were included. Articles were excluded due to lack of relevance, not reporting desired outcomes, or being duplicative in their content. Twenty-five additional articles were identified through screening references of included articles. To identify toxicities in individuals treated with hydroxychloroquine or chloroquine with COVID-19, we searched PubMed on June 10th, 2020: ("Chloroquine" or "Hydroxychloroquine") AND ("Coronavirus" or "COVID-19" or "SARS-CoV-2"). This search resulted in 638 articles. We reviewed articles for reporting of adverse events or toxicities. Most citations were excluded because they did not include original investigations or extrapolated data from subjects that did not have COVID-19; 34 citations were relevant. For the drug-interactions section, relevant classes and agents were identified through a screen of the https://www.covid19-druginteractions.org/ website. We then conducted targeted searches of PubMed up to June 7th 2020 combining "chloroquine" and "hydroxychloroquine" with terms for specific drug classes and drugs identified from the drug-interaction site as potentially relevant. We found 29 relevant articles.

TOXICITY WITH SHORT-TERM USE: : Gastrointestinal toxicities are the most common to occur following initiation of chloroquine or hydroxychloroquine. Nausea, vomiting, and diarrhea account for most reported intolerances. : Alterations in blood glucose concentrations may occur with hydroxychloroquine but are rare with standard therapeutic use. : Short-term use can produce conduction abnormalities. Evidence from COVID-19 treatment suggests QT/QTc prolongation is of concern, particularly when used in combination with azithromycin, although disagreement exists across studies. : Drug eruptions or rashes, followed by cutaneous hyperpigmentation, pruritis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, may occur within days to weeks of exposure but usually resolve with the discontinuation of therapy. : Reported symptoms include confusion, disorientation, and hallucination within 24-48 h of drug initiation. Hemolysis and anemia may occur in patients with glucose-6-phosphate dehydrogenase. Chloroquine treatment of COVID-19 was associated with elevation in creatine kinase and creatine kinase-MB activities with more events in the higher-dose group.

TOXICITY WITH LONG-TERM USE: : Retinopathy is the major dose-limiting toxicity associated with long-term use; the risk is higher with increasing age, dose, and duration of usage. : Long-term use has been associated with conduction abnormalities, cardiomyopathy, and valvular disorders. : Rarely myositis and muscle weakness, extremity weakness, and pseudoparkinsonism have been reported.

TOXICITY IN OVERDOSE

Symptoms in overdose manifest rapidly (minutes to hours) and cardiotoxicity such as cardiovascular shock and collapse are most prominent. Neurotoxic effects such as psychosis and seizure may also occur.

CONCLUSIONS

Hydroxychloroquine is a generally well-tolerated medication. Short-term (days to weeks) toxicity includes gastrointestinal effects and rarely glucose abnormalities, dermatologic reactions, and neuropsychiatric events. Cardiotoxicity became of increased concern with its use in COVID-19 patients. Long-term (years) toxicities include retinopathy, neuromyotoxicity, and cardiotoxicity (conduction abnormalities, cardiomyopathy). Deaths from overdoses most often result from cardiovascular collapse.

摘要

简介

虽然氯喹作为一种抗疟药已经使用了 70 年,但羟氯喹现在用于治疗类风湿关节炎和系统性红斑狼疮等疾病。在 2020 年,羟氯喹(在较小程度上还有氯喹)也因其可能治疗严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)而受到关注。在研究用于治疗由 SARS-CoV-2 引起的 2019 年冠状病毒病(COVID-19)时,出现了对严重不良事件的担忧。

目的

我们综述了羟氯喹和氯喹短期和长期使用以及过量使用时的毒性。

方法

我们使用 Medline(OVID)从其成立到 2020 年 6 月 7 日进行了搜索,使用以下 MeSH 或关键词项:(“Chloroquine/”或“Hydroxychloroquine/”)和(“Adverse Drug Event/”或“Toxicities, Drug/”或“Toxic.mp.”或“Toxicity.mp.”或“Overdose.mp.”)。我们将结果文章限于以英语发表并报告人类受试者的文章。这一搜索产生了 330 篇文章,其中 57 篇被纳入。由于与研究目的无关、未报告所需结果或内容重复,排除了一些文章。通过筛选纳入文章的参考文献,又确定了 25 篇额外的文章。为了确定接受羟氯喹或氯喹治疗的 COVID-19 患者的毒性,我们于 2020 年 6 月 10 日在 PubMed 上进行了搜索:(“Chloroquine”或“Hydroxychloroquine”)和(“Coronavirus”或“COVID-19”或“SARS-CoV-2”)。这一搜索产生了 638 篇文章。我们对报告不良事件或毒性的文章进行了审查。大多数引文被排除,因为它们不包括没有 COVID-19 的原始调查或从没有 COVID-19 的受试者中推断的数据;有 34 条引文是相关的。对于药物相互作用部分,我们通过对 https://www.covid19-druginteractions.org/ 网站的筛选,确定了相关的类别和药物。然后,我们将“chloroquine”和“hydroxychloroquine”与从药物相互作用网站上确定的特定药物类别和药物相关的术语结合起来,对 PubMed 进行了有针对性的搜索,截至 2020 年 6 月 7 日。我们发现了 29 篇相关文章。

短期使用的毒性

胃肠道毒性是氯喹或羟氯喹开始使用后最常见的毒性。恶心、呕吐和腹泻是最常见的不耐受症状。血糖浓度的改变可能发生在羟氯喹治疗中,但在标准治疗中很少见。短期使用可能导致传导异常。来自 COVID-19 治疗的证据表明,QT/QTc 延长是值得关注的,尤其是当与阿奇霉素联合使用时,尽管不同的研究存在分歧。药物皮疹或皮疹,随后是皮肤色素沉着、瘙痒、史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症,可能在接触药物后几天到几周内发生,但通常在停止治疗后会消失。报道的症状包括在药物开始后 24-48 小时内出现意识混乱、定向障碍和幻觉。葡萄糖-6-磷酸脱氢酶缺乏的患者可能发生溶血性贫血和贫血。氯喹治疗 COVID-19 与肌酸激酶和肌酸激酶-MB 活性升高有关,且高剂量组的事件更多。

长期使用的毒性

视网膜病变是与长期使用相关的主要剂量限制毒性;随着年龄、剂量和使用时间的增加,风险会更高。长期使用与传导异常、心肌病和瓣膜疾病有关。很少有肌病和肌肉无力、四肢无力和假性帕金森病的报道。

过量使用的毒性

过量使用的症状在数分钟至数小时内迅速出现(分钟至小时),并以心血管休克和衰竭为最突出的心脏毒性。也可能出现神经毒性作用,如精神病和癫痫发作。

结论

羟氯喹是一种通常耐受性良好的药物。短期(数天至数周)毒性包括胃肠道影响和罕见的血糖异常、皮肤反应和神经精神事件。在 COVID-19 患者中使用时,心脏毒性变得更加令人关注。长期(数年)毒性包括视网膜病变、神经肌肉毒性和心脏毒性(传导异常、心肌病)。心血管衰竭是过量用药导致的死亡的最常见原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验